In conjunction with the American Uveitis Society
Date: Saturday, Oct. 18
Time: 7:50 a.m. to 5:30 p.m.
Location: E450, McCormick Place, Chicago
Registration Now Open
Registration for the Uveitis Subspecialty meeting allows you to:
- Visit the AAO 2014 Exhibition on Saturday, Oct. 18.
- Float among all Subspecialty Day meetings held on Saturday, Oct. 18 – Cornea, Glaucoma, Oculofacial Plastic Surgery, Ocular Oncology and Pathology, Pediatric Ophthalmology, Refractive Surgery, Retina and Uveitis.
Hotel Reservations Now Open
C. Stephen Foster, MD; Russell W. Read, MD, PhD
C. Stephen Foster, MD; Henry J. Kaplan, MD; Robert B. Nussenblatt, MD; Russell W. Read, MD, PhD; Albert T. Vitale, MD
The mission of the 2014 Uveitis Subspecialty Day is to provide attendees with a comprehensive, state-of-the-art update on the treatment and management of uveitis disorders.
The intended audience for this program includes general ophthalmologists, comprehensive ophthalmologists, uveitis specialists and other ophthalmologic subspecialists (cornea, retina, etc.) and allied health personnel who are involved in the management of patients with uveitis and ocular inflammatory diseases.
To provide attendees with a comprehensive update on the challenges in the diagnosis and management of uveitis and various ocular inflammatory diseases, and to identify and discuss the current work and studies that may lead to new management approaches and standards of care in the future.
Upon completion of this activity, participants should be able to:
- Identify the challenges in recognizing the various forms of ocular inflammatory diseases, including cicatricial pemphigoid, retinal vasculitis, and anterior, intermediate, and posterior uveitis.
- Construct a differential diagnosis for various forms of uveitis.
- Classify the principles of diagnosis of ocular inflammatory disorders in order to initiate appropriate, disease-directed evaluations.
- Identify the important and appropriate role of immunomodulatory therapy for patients with selected, specific ocular inflammatory diseases and also for patients with steroid-dependent inflammation.
- Describe the various gaps that currently exist in the management of uveitis and ocular inflammatory diseases such as failure to recognize the sight-saving benefits of pursuing durable remission, failure to understand the paradigm shift away from corticosteroid monotherapy to a stepladder algorithm and failure to recognize the elements essential to successful control of uveitic glaucoma, among others.
- Describe the potential new treatments for uveitis and ocular inflammatory diseases, including selected therapeutic agents in development, based on recent and current work and studies.
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this live activity for a maximum of 7 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Attendees registered as exhibitors, spouses or guests are not eligible for CME credits.